LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer

444OPHASE IB TRIAL TRIAL OF RG7116, A GLYCOENGINEERED MONOCLONAL ANTIBODY TARGETING HER3, IN COMBINATION WITH CETUXIMAB OR ERLOTINIB IN PATIENTS WITH ADVANCED/METASTATIC TUMORS OF EPITHELIAL CELL ORIGIN EXPRESSING HER3 PROTEIN

(2017) U.N. Lassen et al.   ANNALS OF ONCOLOGY

Translating gastric cancer genomics into targeted therapies

(2016) Yvonne L.E. Ang et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

(2016) Martine Piccart-Gebhart et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

(2016) Debora de Melo Gagliato et al.   Oncotarget

Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer

(2015) Makoto Nishio et al.   LUNG CANCER

Abstract C120: Phase I study of the safety and tolerability of LJM716 in Japanese patients with advanced solid tumors

(2015) TAITO ESAKI et al.   MOLECULAR CANCER THERAPEUTICS

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial

(2015) Eric Assenat et al.   Oncotarget

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

(2015) Jeanne Mendell et al.   EBioMedicine

Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC

(2015) Kaihua Zhang et al.   Oncotarget

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

(2014) Hiroshi Wakui et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer

(2014) A. Ring et al.   CLINICAL CANCER RESEARCH

Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models

(2014) K. Meetze et al.   CLINICAL CANCER RESEARCH

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110  Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

(2013) J. T. Garrett et al.   CANCER RESEARCH

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

(2013) A. P. Garner et al.   CANCER RESEARCH

Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2013) P. LoRusso et al.   CLINICAL CANCER RESEARCH

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients

(2013) Douglas A. Rubinson et al.   INVESTIGATIONAL NEW DRUGS

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential Therapeutic Significance of HER-Family in Esophageal Squamous Cell Carcinoma

(2012) Koji Kono et al.   Annals of Thoracic and Cardiovascular Surgery

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2012) Javier Cortés et al.   JOURNAL OF CLINICAL ONCOLOGY

Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

(2011) Timothy R. Wilson et al.   CANCER CELL

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

(2010) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics

(2010) Dhara N. Amin et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract

(2009) Noor Al-Dasooqi et al.   CURRENT DRUG TARGETS

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

(2009) N. Jura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer

(2008) C. L. Arteaga et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical aspects of the Bayesian approach to phase I cancer trials

(2008) Beat Neuenschwander et al.   STATISTICS IN MEDICINE